ClinicalTrials.gg
WithdrawnNCT06973109Updated Jun 4, 2026

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes

A Phase 2 interventional study of Romosozumab and Alendronate (Fosamax) in Osteoporosis, Post-menopausal, sponsored by University of Pittsburgh. Withdrawn at 1 site in United States. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by University of Pittsburgh · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Investigator left the institution

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
65 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.

Enrollment
12th of 12
0 · median 268
Started
2026
the only one that year
Phase 2
3 of 12
none open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
University of Pittsburgh

Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 12th largest by enrollment, is the only one that started in 2026, is one of 3 in phase 2, and was the 11th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 65 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing romosozumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if romosozumab (Evenity) can improve bone and muscle health in postmenopausal women with osteoporosis who are undergoing lumbar spine surgery. The main questions it aims to answer are:

  • Does romosozumab improve bone strength and reduce the risk of complications during and after spine surgery?
  • Does romosozumab increase muscle mass and help patients recover better from surgery?

Researchers will compare romosozumab (a monthly injection) to alendronate (a weekly pill), both approved treatments for osteoporosis, to see which is more effective in this surgical setting. Participants will:

  • Be randomly assigned to receive romosozumab or alendronate
  • Take standard vitamin supplements and receive a one-time dose of zoledronic acid near the end of the study
  • Attend five study visits over about 12 months
  • Undergo bone scans, muscle imaging, and complete health questionnaires before and after surgery
03

Conditions studied

  • Osteoporosis, Post-menopausal
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female
  • Diagnosed with osteoporosis (T-score ≤ -2.5).
  • Scheduled for or planning posterior lumbar fusion for degenerative disease, at least 3 months in the future.
  • Able to provide .

Exclusion criteria

Exclusion Criteria:

  • History of prior spinal surgery.
  • Male sex.
  • Current or prior use of osteoporosis medications within the past 3 years.
  • Current use of anabolic agents other than romosozumab.
  • Current use of androgen receptor (AR) modulators, such as testosterone replacement therapy or selective androgen receptor modulators (SARMs).
  • Severe renal impairment ( \< 30 mL/min/1.73m²).
  • Known to romosozumab, alendronate or zoledronic acid.
  • Severe spinal deformity.
  • Active or history of malignancy within the past 5 years.
  • Any secondary cause of decreased BMD (e.g., hyperparathyroidism).
  • Stroke or myocardial infarction in the past year.
  • Planned fusion involving more than 4 levels.
  • Uncorrected hypocalcemia and/or hypovitaminosis D
  • Esophageal abnormalities
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Romosozumab + Placebo Alendronate

    Participants will receive monthly subcutaneous injections of romosozumab (210 mg, one injection per arm) for 12 months, along with weekly oral placebo alendronate. Surgery will be performed 3 months after treatment initiation. DXA and CT scans will assess bone density and muscle mass. Functional outcomes will be evaluated via PROMs at baseline and follow-up.

    Drug: Romosozumab · Drug: Placebo Alendronate

  • Active comparator
    Alendronate + Placebo Romosozumab

    Participants will receive weekly oral doses of alendronate (70 mg) and monthly subcutaneous placebo injections mimicking romosozumab. Surgery will occur after 3 months of treatment. Bone density, muscle mass, and functional outcomes will be assessed similarly to the experimental arm.

    Drug: Alendronate (Fosamax) · Drug: Placebo Romosozumab

Interventions

  • Monthly subcutaneous injection (210 mg total dose) administered as two separate 105 mg injections, one per arm. Administered for 12 months to female patients ≥65 years undergoing spine surgery.

    Also known as: Evenity

  • DrugAlendronateStudies of AlendronateAlendronate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Weekly oral dose (70 mg) administered for 12 months. Used as active comparator in control arm of study.

    Also known as: Fosamax

  • DrugPlacebo Romosozumab

    Monthly subcutaneous injections mimicking romosozumab in appearance and administration schedule. Administered to control group.

  • DrugPlacebo Alendronate

    Weekly oral placebo pill mimicking alendronate. Administered to treatment group.

06

What researchers measure

Primary outcomes

  1. Change in Hounsfield Units (HU) at L1 Vertebra

    This measure assesses changes in vertebral bone quality by measuring Hounsfield Units (HU) at the L1 vertebra via CT scans. HU values will be compared from baseline to post-treatment between the romosozumab and alendronate groups to evaluate bone density improvement.

    Time frame: Baseline, 3 months post-op, and 9 months post-op

  2. Change in Vertebral Bone Mineral Density (BMD) at L1

    This measure evaluates the efficacy of romosozumab in improving vertebral bone density in older adults undergoing spine surgery. BMD will be measured using DXA scans of the total hip and compared from baseline to post-treatment between the romosozumab and alendronate groups.

    Time frame: Baseline, 3 months post-op, and 9 months post-op

Secondary outcomes

  1. Change in L3 skeletal muscle index (L3 SMI)

    This measure assesses the impact of romosozumab on muscle mass in patients undergoing spine surgery. L3SMI will be calculated from axial CT scans at the L3 vertebral level, normalized by patient height squared. Changes from baseline will be compared between treatment and control groups.

    Time frame: Baseline, 3 months post-op, and 9 months post-op

  2. Change in Oswestry Disability Index (ODI)

    This measure evaluates change in patient-reported disability related to lower back pain using the ODI. Scores range from 0 to 100, with higher scores indicating greater disability.

    Time frame: Baseline and 9 months post-op

  3. Change in Visual Analog Scale (VAS) for Pain

    This measure evaluates change in pain intensity using the VAS, which ranges from 0 (no pain) to 10 (worst possible pain).

    Time frame: Baseline and 9 months post-op

07

Study locations

1 site
  • University of Pittsburgh Medical Center (UPMC) - Presbyterian Hospital
    Pittsburgh, Pennsylvania 15213, United States
08

References and documents

Individual participant data

Plan to share: Yes — All individual participant data (IPD) collected during the trial that underlies published results will be shared, including de-identified data on demographic variables, dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD) measurements, Hounsfield unit (HU) values from CT scans, L3 skeletal muscle index, radiographic fusion outcomes, hardware complication data, and patient-reported outcomes (ODI and VAS scores). Data will be made available to other qualified researchers upon reasonable request following publication of primary results, contingent on IRB approval and data use agreements.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: IPD and supporting information will be available beginning 12 months after publication of the primary results and will remain available for 5 years thereafter.

Access criteria: Qualified researchers with a methodologically sound proposal may request access to the data by contacting the study principal investigator. Requestors will need to complete a data use agreement. Data will be provided via a secure online platform after IRB approval and review of the request by the study team.

Data sharing details ↗ · www.scoli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Mar 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
May 15, 2025
StartEst.
Jun 20, 2026
Primary completionEst.
Mar 2, 2027
CompletionEst.
Jun 2027
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06973109
Collaborators
Amgen, The Greg Beckwith Foundation
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Jun 20, 2026 (estimated)
Primary completion
Mar 2, 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

Nitin Agarwal, M.D.
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion